Dedicated state-of-the-art Phase-I units in Ahmedabad (India), Toronto (Canada) & Novum (USA) enable us to have a synergistic approach across geographies for timeline and cost advantages. Till date, Lambda has successfully executed over 43 phase-1 studies in the last 5 years for various formulations including Oral, Parenteral, Inhalers, Topical, Transdermal, Nasal Sprays, Injectables, Pessaries, Suppositories etc.
Lambda has strong technical expertise in handling studies like:
- Single Ascending Dose (SAD) - First in Man
- Multiple Ascending Dose (MAD)
- BA/BE Bio comparison
- Drug-Drug Interaction
- Food-Drug Interaction
- PK-PD
- Proof-of-concept
- Irritation, Sensitization, Adhesion
- Cardiac Safety
- Vasoconstrictor Studies for Topical Cortico steroids
- Special Patient Populations
- Potency Ranking Studies
- Drug-Device Combinations
- Food Effect Studies
NCE Therapeutic Categories

Analgesics

Anticonvulsants

Antidepressants

Anti–inflammatory Agents

Antiviral

Antibacterial

Antidementia Agents

Antifungal

Antimigraine Agents

Blood Glucose Regulators

Blood Modifiers

Cardiovascular Agents

Central Nervous System Agents

Dermatological Agents

Gastrointestinal Agents

Hormonal Agents

Immunological Agents

Ophthalmic Agents

Respiratory Agents

Vaccines

Phytopharmaceuticals

Inflammatory Bowel Diseases

Antiretrovirals
Value Proposition
NORTH AMERICA
- FiH Or SAD study in Canada & US
- Faster regulatory approval
- Parallel submission for MAD study in India
- Study starts with healthy subjects followed by patient cohorts
INDIA
- Cost-effective option for subsequent Phase-1 studies
- Easier Access for Renal and Liver impaired subjects study
VALUE PROPOSITION
- Cost-effective business model (Hybrid)
- Faster Turn Around Time
- Global scientific overview
- Flexible Operational approach